Interleukin-17 and B cell-activating factor in Kawasaki disease and juvenile systemic lupus erythematosus

Abstract

Get full access to this article

View all access options for this article.

References

Diniz

Almeida

Aikawa

Sallum

Sakane

Silva

. Kawasaki disease and juvenile systemic lupus erythematosus. Lupus 2012; 21: 89–92.

Park

. Epidemiology of Kawasaki disease in Korea. Korean J Pediatr 2008; 51: 452–456.

Sohn

Noh

Chang

Shin

Kim

. Circulating interleukin 17 is increased in the acute stage of Kawasaki disease. Scand J Rheumatol 2003; 32: 364–366.

Doi

Takeda

Sakurai

. Altered immunoglobulin A and M levels associated with changes in BAFF and APRIL after administration of intravenous immunoglobulin to treat Kawasaki disease. J Investig Allergol Clin Immunol 2010; 20: 413–418.

Shin

Lee

Kang

. Effector T-cell subsets in systemic lupus erythematosus: update focusing on Th17 cells. Curr Opin Rheumatol 2011; 23: 444–448.

Doreau

Belot

Bastid

. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009; 10: 778–785.